Knight Therapeutics Company Profile (CVE:GUD)

About Knight Therapeutics

Knight Therapeutics logoKnight Therapeutics Inc. (Knight) is a specialty pharmaceutical company. The Company is focused on developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products. The Company's product pipeline consists of the product Impavido (miltefosine), an alkyllysophospholipid analogue drug with in vitro activity against the promastigote and amastigote stages of Leishmania species. Impavido is an oral agent indicated for the treatment of visceral and cutaneous leishmaniasis and was included in the World Health Organization (WHO) essential medicines list as an anti-leishmaniasis medicine.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: CVE
  • Symbol: GUD
  • CUSIP:
Key Metrics:
  • Previous Close: $9.61
  • 50 Day Moving Average: $8.76
  • 200 Day Moving Average: $8.28
  • 52-Week Range: C$132,701,000.00 - C$5.89
  • Trailing P/E Ratio: 59.69
  • P/E Growth: 3203.33
  • Market Cap: $1.28B
  • Outstanding Shares: 132,701,000
Additional Links:

Analyst Ratings

Consensus Ratings for Knight Therapeutics (CVE:GUD) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Knight Therapeutics (CVE:GUD)
Show:
DateFirmActionRatingPrice TargetDetails
3/6/2015MackieInitiated CoverageBuyView Rating Details
1/2/2015LB SecuritiesReiterated RatingHoldView Rating Details
(Data available from 9/25/2014 forward)

Earnings

Earnings History for Knight Therapeutics (CVE:GUD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Knight Therapeutics (CVE:GUD)
Current Year EPS Consensus Estimate: $0.10 EPS

Dividends

Dividend History for Knight Therapeutics (CVE:GUD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Knight Therapeutics (CVE:GUD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Knight Therapeutics (CVE:GUD)
DateHeadline
News IconLatest Reports on B2Gold, Knight Therapeutics, Lundin Mining, and Turquoise Hill Resources (CVE:GUD)
news.investornetwork.com - September 21 at 9:34 AM
capitalcube.com logoETF’s with exposure to Knight Therapeutics, Inc. : September 13, 2016 (CVE:GUD)
www.capitalcube.com - September 14 at 9:35 AM
theglobeandmail.com logoIf $10,000 fell into your lap, what would you do? (CVE:GUD)
www.theglobeandmail.com - September 1 at 8:16 AM
News IconFormer Paladin Labs CFO Named President at Knight Therapeutics (CVE:GUD)
www.biospace.com - August 18 at 8:20 AM
finance.yahoo.com logoKnight Medison Relationship Continues to Pay Dividends (CVE:GUD)
finance.yahoo.com - August 15 at 10:16 AM
finanznachrichten.de logoSIFI S.p.A. and Knight Therapeutics Announce Canadian License Agreement for NETILDEX (CVE:GUD)
www.finanznachrichten.de - August 2 at 5:37 PM
marketwired.com logoSIFI S.p.A. and Knight Therapeutics Announce Canadian License Agreement for NETILDEX™ (CVE:GUD)
www.marketwired.com - August 2 at 5:37 PM
marketwired.com logo3D Signatures Inc. and Plicit Capital Corp. Execute Definitive Licencing and Distribution Agreements With Knight Therapeutics Inc. (CVE:GUD)
www.marketwired.com - July 22 at 8:17 AM
marketwired.com logoKnight Acquires Minor Stake in Pediapharm (CVE:GUD)
www.marketwired.com - July 15 at 4:25 PM
finanznachrichten.de logoKNIGHT THERAPEUTICS INC (CVE:GUD)
www.finanznachrichten.de - May 26 at 12:31 PM
finance.yahoo.com logo3D Signatures Inc. and Plicit Capital Corp. Increase Minimum Financing and Receive Lead Order From and Enter Into Advisory Agreement With Knight Therapeutics Inc. (CVE:GUD)
finance.yahoo.com - May 26 at 12:16 PM
finance.yahoo.com logoKnight Reports First Quarter 2016 Results (CVE:GUD)
finance.yahoo.com - May 10 at 6:00 AM
finance.yahoo.com logoKnight Blooms at Healthcare Investor Conference in Toronto (CVE:GUD)
finance.yahoo.com - April 25 at 8:00 AM
finance.yahoo.com logoKnight Receives NOD from Health Canada for ATryn(R) (CVE:GUD)
finance.yahoo.com - April 25 at 8:00 AM
finance.yahoo.com logoKnight Finds EMPAthetic Partner for Neuragen(R) in the Middle East (CVE:GUD)
finance.yahoo.com - April 25 at 8:00 AM
biz.yahoo.com logoQ4 2015 KNIGHT THERAPEUTICS Inc Earnings Release - Time Not Supplied (CVE:GUD)
biz.yahoo.com - March 24 at 7:07 AM
finance.yahoo.com logoKnight Reports Fourth Quarter and Year-Ended December 31, 2015 Results (CVE:GUD)
finance.yahoo.com - March 24 at 6:00 AM
finance.yahoo.com logoKnight Receives Dividend From Medison (CVE:GUD)
finance.yahoo.com - March 23 at 8:00 AM
finance.yahoo.com logoKnight Partner Profounda Inc. Launches Impavido in U.S. (CVE:GUD)
finance.yahoo.com - March 22 at 8:03 AM
finance.yahoo.com logoProfounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States (CVE:GUD)
finance.yahoo.com - March 22 at 7:59 AM
finance.yahoo.com logoKnight Obtains Impavido Worldwide Rights (CVE:GUD)
finance.yahoo.com - March 15 at 8:00 AM
finance.yahoo.com logoKnight Therapeutics Inc. (GUD.TO) (CVE:GUD)
finance.yahoo.com - January 16 at 2:29 PM
finance.yahoo.com logoKnight Loan to Extenway Impaired (CVE:GUD)
finance.yahoo.com - December 22 at 8:00 AM
capitalcube.com logoKnight Therapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers (CVE:GUD)
www.capitalcube.com - December 18 at 9:42 AM
finance.yahoo.com logoKnight Takes Right Angle With 60 Degrees Pharmaceuticals LLC (CVE:GUD)
finance.yahoo.com - December 11 at 8:00 AM
capitalcube.com logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : December 9, 2015 (CVE:GUD)
www.capitalcube.com - December 9 at 9:21 AM
finance.yahoo.com logoCRH Makes GUD on Knight Secured Loan (CVE:GUD)
finance.yahoo.com - November 25 at 8:00 AM
finance.yahoo.com logoKnight to Present at the TD Securities Technology & Healthcare Conference in Toronto (CVE:GUD)
finance.yahoo.com - November 17 at 8:00 AM
finance.yahoo.com logoKnight Partner FOCUSed on Growth (CVE:GUD)
finance.yahoo.com - November 16 at 8:00 AM
finance.yahoo.com logoKnight Supports Operation Antibe (CVE:GUD)
finance.yahoo.com - November 16 at 8:00 AM
capitalcube.com logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : November 11, 2015 (CVE:GUD)
www.capitalcube.com - November 11 at 9:37 AM
finance.yahoo.com logoKnight Reports Third Quarter Financial 2015 Results (CVE:GUD)
finance.yahoo.com - November 11 at 6:00 AM
finance.yahoo.com logoThe Knight Medison Relationship Already Paying Dividends (CVE:GUD)
finance.yahoo.com - November 2 at 8:00 AM
capitalcube.com logoKnight Therapeutics, Inc. – Value Analysis (TORONTO:GUD) : October 28, 2015 (CVE:GUD)
www.capitalcube.com - October 28 at 1:55 PM
capitalcube.com logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : October 15, 2015 (CVE:GUD)
www.capitalcube.com - October 15 at 10:11 AM
finance.yahoo.com logoKnight Profounda U.S. Partner for Impavido (CVE:GUD)
finance.yahoo.com - September 28 at 8:00 AM
capitalcube.com logoKnight Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : September 15, 2015 (CVE:GUD)
www.capitalcube.com - September 15 at 10:56 AM

Social

Knight Therapeutics (CVE:GUD) Chart for Sunday, September, 25, 2016


Last Updated on 9/25/2016 by MarketBeat.com Staff